Larimar Therapeutics (LRMR) Current Leases (2019 - 2026)

Larimar Therapeutics (LRMR) has reported Current Leases for 8 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Leases rose 6.47% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (up 6.47% YoY), and the FY2025 full-year result was $1.1 million, up 4.25% from the prior year.
• Current Leases advanced to $1.2 million in Q2 2026 per LRMR's latest filing, from $1.1 million in the prior quarter.
• Across five years, Current Leases topped out at $1.2 million in Q2 2026 and bottomed at $566000.0 in Q2 2023.
• Historically, Current Leases has averaged $869588.2 across 5 years, with a median of $837000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Leases slipped 11.29% in 2023, then soared 75.27% in 2024.
• Over 5 years, Current Leases stood at $611000.0 in 2022, then jumped by 36.99% to $837000.0 in 2023, then climbed by 26.64% to $1.1 million in 2024, then rose by 4.25% to $1.1 million in 2025, then gained by 8.78% to $1.2 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $1.2 million, $1.1 million, and $1.2 million for Q2 2026, Q4 2025, and Q3 2025 respectively.